Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 10, 2014 - Issue 10
Submit an article Journal homepage
1,947
Views
10
CrossRef citations to date
0
Altmetric
Editorials

IL-18: a new player in immunotherapy for age-related macular degeneration?

Matthew CampbellThe Ocular Genetics Unit, Department of Genetics, Trinity College Dublin, Dublin 2, Ireland
,
Sarah DoyleDepartment of Clinical Medicine, National Children’s Research Centre, School of Medicine, Our Lady’s Hospital for Sick Children, Trinity College Dublin, Dublin 2, Ireland
&
Peter HumphriesThe Ocular Genetics Unit, Department of Genetics, Trinity College Dublin, Dublin 2, IrelandCorrespondence[email protected]
Pages 1273-1275 | Published online: 21 Aug 2014

References

  • Doyle SL, Ozaki E, Brennan K, et al. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration. Sci Transl Med 2014;6(230):230
  • Doyle SL, Campbell M, Ozaki E, et al. NLRP3 plays a protective role during the development of age related macular degeneration through the induction of IL-18 by drusen components. Nat Med 2012;18(5):791-8
  • Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378(6552):88-91
  • Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 1999;13(15):2195-202
  • Qiao H, Sonoda KH, Ikeda Y, et al. Interleukin-18 regulates pathological intraocular neovascularization. J Leukoc Biol 2007;81(4):1012-21
  • Qiao H, Sonoda KH, Sassa Y, et al. Abnormal retinal vascular development in IL-18 knockout mice. Lab Invest 2004;84(8):973-80
  • Shen J, Choy DF, Yoshida T, et al. Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF. J Cell Physiol 2014;229(8):974-83
  • Robertson MJ, Kirkwood JM, Logan TF, et al. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 2008;14:3462-9
  • Robertson MJ, Mier JW, Logan T, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006;12:4265-73
  • Golab J, Stoklosa T. Technology evaluation: SB-485232, GlaxoSmithKline. Curr Opin Mol Ther 2005;7:85-93
  • Tarallo V, Hirano Y, Gelfand BD, et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 2012;149:847-59
  • Gelfand BD, Hirano Y, et al. Pathophysiology of AMD and retinopathies. ARVO 2014 Annual Meeting Abstracts, 06 May, 2014; 3:45 PM–5:30 PM. S 310E-H Paper Session
  • Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452(7187):591-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.